Apixaban Pharmacokinetics and Bioequivalence of Two Tablet Formulations: A Randomized, Open‐Label, Crossover Study, Fasting Condition in Healthy Indonesian Volunteers
Clinical Pharmacology in Drug Development · 2024
DOI: 10.1002/cpdd.1409 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2024. Verfasst von Chuei Wuei Leong und 9 weiteren Autor:innen. Beteiligte Einrichtung: Duopharma Innovation Sdn. Bhd., Shah Alam, Selangor, Malaysia. Hauptthemen laut MEDLINE: Therapeutic Equivalency, Pyridones, Pyrazoles, Cross-Over Studies. Die Arbeit nennt 24 Literaturangaben. Gefördert von: Duopharma Biotech Berhad.
Abstract (Originalsprache)
The present study aimed to assess the bioequivalence of a new apixaban generic with reference formulation. Twenty‐six healthy volunteers were recruited for an open‐label, balanced, randomized, 2‐treatment, 2‐sequence, 2‐period, single oral dose study. Following overnight fasting, each volunteer received 5 mg of apixaban test and reference formulations as single doses, separated by a 1‐week washout period. Twenty blood samples were collected at predose and multiple time points between 0.5 and 72 hours after dosing. A validated ultra‐performance liquid chromatography‐tandem mass spectrometry detection method following a protein precipitation step was implemented to determine apixaban concentrations. Noncompartmental analysis was used to derive the pharmacokinetic parameters, which were then compared between the test and reference products using a multivariate analysis of variance. The pharmacokinetic parameters of the test product were not statistically different from the reference product, and the 90% confidence intervals of apixaban natural log‐transformed area under the concentration‐time curve from time 0 to infinity, area under the concentration‐time curve from time 0 to the last measurable concentration, and maximum concentration were within 80%‐125% based on the bioequivalence acceptance range criteria. The test and reference formulations of apixaban are bioequivalent in healthy subjects under fasting conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Duopharma Innovation Sdn. Bhd., Shah Alam, Selangor, Malaysia.
- PT Equilab International, Jakarta, Indonesia.
Förderung
- Duopharma Biotech Berhad
Zitieren
APA
Leong, C. W., Yee, K. M., Liew, I., Khaleb, N. A., Ahmad, S., Rani, T. A., Lau, K. J., Yunaidi, D. A., Simanjuntak, R., & Ginanjar, V. A. (2024). Apixaban Pharmacokinetics and Bioequivalence of Two Tablet Formulations: A Randomized, Open‐Label, Crossover Study, Fasting Condition in Healthy Indonesian Volunteers. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1409
Vancouver
Leong CW, Yee KM, Liew I, Khaleb NA, Ahmad S, Rani TA, et al. Apixaban Pharmacokinetics and Bioequivalence of Two Tablet Formulations: A Randomized, Open‐Label, Crossover Study, Fasting Condition in Healthy Indonesian Volunteers. Clinical Pharmacology in Drug Development. 2024. doi:10.1002/cpdd.1409
BibTeX
@article{Leong2024,
author = {Leong, Chuei Wuei and Yee, Kar Ming and Liew, Ivan and Khaleb, Nur Athirah and Ahmad, Shahnun and Rani, Tracy Ann and Lau, Kheng Jim and Yunaidi, Danang Agung and Simanjuntak, Ronal and Ginanjar, Vicky A},
title = {Apixaban Pharmacokinetics and Bioequivalence of Two Tablet Formulations: A Randomized, Open‐Label, Crossover Study, Fasting Condition in Healthy Indonesian Volunteers},
journal = {Clinical Pharmacology in Drug Development},
year = {2024},
doi = {10.1002/cpdd.1409}
}
EUVIMED